George Perry to Hypoglycemic Agents
This is a "connection" page, showing publications George Perry has written about Hypoglycemic Agents.
Connection Strength
0.657
-
da Silva AMP, Janu?rio Campos Cardoso L, Batista S, Gon?alves OR, Paranhos T, Teixeira IPS, Guimar?es PD, Espinosa Franco B, Cal H, Salles JEN, Perry G, H?ilund-Carlsen PF, Santos DH. Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study. J Diabetes Complications. 2026 May; 40(5):109306.
Score: 0.207
-
Wang W, Davis PB, Qi X, Gurney M, Perry G, Volkow ND, Kaelber DC, Xu R. Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study. J Alzheimers Dis. 2025 Aug; 106(4):1509-1522.
Score: 0.198
-
Wang W, Wang Q, Qi X, Gurney M, Perry G, Volkow ND, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024 12; 20(12):8661-8672.
Score: 0.189
-
Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, Perry G, Smith MA, Zhu X, Moreira PI. Insulin is a two-edged knife on the brain. J Alzheimers Dis. 2009; 18(3):483-507.
Score: 0.063